Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Future research directions for breast cancer

Giuseppe Curigliano • 9 Dec 2021
SABCS 2021
Breast Cancer Antibodies Fulvestrant Trastuzumab deruxtecan
DESTINY-Breast06 NATALEE

Giuseppe Curigliano, MD, PhD, University of Milan and European Institute of Oncology, Milan, Italy, discusses what he thinks are the most important trials and future research directions in ER-positive, HER2-positive, and triple-negative breast cancer. Oral selective estrogen receptor degraders (SERDs) were an exciting topic at SABCS 2021, with promising data being presented. Dr Curigliano also discusses the NATALEE (NCT03701334) and DESTINY-Breast06 (NCT04494425) trials. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Disclosures

Consultation fees from Pfizer, Roche, Astra Zeneca, BMS, Daichii Sankyo, Seagen, Gilead, Novartis, Lilly; Ellipsis, Merck

More from Giuseppe Curigliano

Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancer
6:54
Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancer
Giuseppe Curigliano • 9 Dec 2021
PROCURE: Genomic signatures and adjuvant chemotherapy for breast cancer in Europe
2:49
PROCURE: Genomic signatures and adjuvant chemotherapy for breast cancer in Europe
Giuseppe Curigliano • 9 Dec 2021
Reflecting on the use of CDK4/6 inhibitors in HR+ breast cancer
1:51
Reflecting on the use of CDK4/6 inhibitors in HR+ breast cancer
Giuseppe Curigliano • 25 Mar 2021
Highlights from the St. Gallen Consensus Panel
3:10
Highlights from the St. Gallen Consensus Panel
Giuseppe Curigliano • 24 Mar 2021

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals